P-glycoprotein inhibition: The past, the present and the future

No Thumbnail Available
File version
Author(s)
Darby, Richard AJ
Callaghan, Richard
McMahon, Roisin M
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2011
Size
File type(s)
Location
License
Abstract

The multidrug resistant phenotype of cancer cells can often result from the over-production of a number of ATP binding cassette (ABC) transporters, including P-glycoprotein (P-gp). These multidrug efflux transporters expel administered anti-cancer drugs from the cancer cell, preventing sufficient intracellular drug accumulation and ultimately, drug efficacy. The co-administration of compounds that can impede the efflux of chemotherapeutic agents by these ABC transporters can concomitantly modulate various cytochrome P450 (CYP450) enzymes, consequently impacting upon anti-cancer drug metabolism. This can further result in unfavourable drug-drug interactions and altered pharmacokinetic properties of the administered anti-cancer drugs with knock-on adverse cytotoxic side effects. This review will discuss some of the P-gp inhibitors designed and employed to date, as well as expressing our views of the shortcomings of their design strategy. We present a medicinal chemists wish list for the paradigmatic P-gp inhibitor molecule and examine the possible future strategies that could be implemented to achieve its design.

Journal Title

Current Drug Metabolism

Conference Title
Book Title
Edition
Volume

12

Issue

8

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Pharmacology and pharmaceutical sciences

Pharmacology and pharmaceutical sciences not elsewhere classified

Persistent link to this record
Citation
Collections